title: Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha.
abstract: Colonic ischemia (CI) is a rare complication of high-dose interleukin-2 (IL-2) immunotherapy. This complication occurred in three of 141 patients (2.1%) with metastatic cancer treated with high-dose IL-2 therapy; CI only developed in patients receiving interferon-alpha (IFN) with IL-2 (three of 21, 14%) compared with none of 120 in those patients receiving IL-2 alone (P equals 0.0009). Severe diarrhea (greater than or equal to 7 bowel movements/day) also was significantly more common in patients receiving IFN with IL-2 (six of 21, 29%) than in those receiving IL-2 alone (three of 120, 2.5%, P equals 0.001) and preceded the clinical diagnosis of CI in all three patients. Three of nine patients with severe diarrhea had CI. Hematochezia occurred in four patients, all of whom received IFN with IL-2; three had CI, and the other patient had nonspecific colitis. Differences in vasopressor use did not explain the increased risk of CI in patients receiving IFN; those receiving IFN with IL-2 required phenylephrine less often than patients receiving IL-2 alone (P equals 0.01). The administration of lymphokine-activated killer (LAK) cells had no significant effect on the incidence of CI, severe diarrhea, peritonitis, or vasopressor use; two of three patients with CI, however, had their ischemic episode within 24 hours after the last of three LAK cell infusions. In conclusion, CI is an unusual complication of high-dose IL-2 and IFN immunotherapy. In patients receiving such combination therapy, severe diarrhea is a risk factor for the subsequent occurrence of CI.
authors.affiliation: Department of Oncology, Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, NY 10467.
authors.forename: J A
authors.initials: JA
authors.lastname: Sparano
authors.forename: J P
authors.initials: JP
authors.lastname: Dutcher
authors.forename: R
authors.initials: R
authors.lastname: Kaleya
authors.forename: G
authors.initials: G
authors.lastname: Caliendo
authors.forename: J
authors.initials: J
authors.lastname: Fiorito
authors.forename: S
authors.initials: S
authors.lastname: Mitsudo
authors.forename: R
authors.initials: R
authors.lastname: Shechner
authors.forename: S J
authors.initials: SJ
authors.lastname: Boley
authors.forename: R
authors.initials: R
authors.lastname: Gucalp
authors.forename: N
authors.initials: N
authors.lastname: Ciobanu
mesh_terms: D002292:Carcinoma, Renal Cell / Q000628:therapy; D003106:Colon / Q000098:blood supply*; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects* / Q000627:therapeutic use; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D007511:Ischemia / Q000209:etiology*; D007680:Kidney Neoplasms / Q000628:therapy; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies
chemical_list: D007370:Interferon Type I; D007376:Interleukin-2; D011994:Recombinant Proteins